لخّصلي

?The ReEBOV finger-prick rapid diagnostic test achieved 92% specificity and 100% sensitivity in both point-of-contact (POC) testing and reference laboratory testing in 28 Ebola-positive patients by reverse transcription polymerase chain reaction (RT-PCR) and 77 Ebola-negative individuals by RT-PCR ?It offers a particularly attractive approach in the event of an active Ebola outbreak because infected individuals do not become infectious until clinical symptoms appear.It helps countries be able to quickly and accurately determine the presence or absence of infection in individuals at risk of contracting the virus.Point-of-care diagnostic testing for EBOV.?

 The European Center for Disease Control and Prevention has published several key papers describing noteworthy aspects of the Ebola outbreak in West Africa, such as the dynamics of early transmission of the virus, the activities of case management centres, the proportion of healthcare workers infected, the transmission tree of the virus, and the direct impact of experiences from the field , among other things
 Point-of-care diagnostic testing for EBOV. It helps countries be able to quickly and accurately determine the presence or absence of infection in individuals at risk of contracting the virus. It offers a particularly attractive approach in the event of an active Ebola outbreak because infected individuals do not become infectious until clinical symptoms appear.
 The ReEBOV finger-prick rapid diagnostic test achieved 92% specificity and 100% sensitivity in both point-of-contact (POC) testing and reference laboratory testing in 28 Ebola-positive patients by reverse transcription polymerase chain reaction (RT-PCR) and 77 Ebola-negative individuals by RT-PCR
 ReEBOV is the only rapid diagnostic test approved for use through Emergency Use Authorization from the World Health Organization and the Food and Drug Administration.